Featured News
AMPEL BioSolutions’ Precision Medicine Breakthrough Predicts Drug Options with RNA Analytics & Machine Learning
Virginia Workforce Award to AMPEL BioSolutions
AMPEL on Bloomberg Markets
Lupus, coronary artery disease share genetic risk factors; data may lead to early testing
Local company unveils blood test to find treatments for chronic pain
Local company unveils blood test to find treatments for chronic pain
AMPEL BioSolutions Enters MDx Market With Lupus, Dermatology Gene Expression Assays
Innovator-of-Year to AMPEL
Lupus
Lupus, coronary artery disease share genetic risk factors; data may lead to early testing
Researchers have identified shared genetic risk factors for systemic lupus erythematosus and coronary artery disease, according to data published in Cell Reports Medicine.
AMPEL BioSolutions Enters MDx Market With Lupus, Dermatology Gene Expression Assays
After nine years in business, precision medicine company AMPEL BioSolutions is broadening its market from pharmaceutical companies to healthcare providers and their patients.
AMPEL BioSolutions’ Machine Learning Breakthrough Predicts Chronic Disease Flares from a Blood Sample
Dermatology
AMPEL BioSolutions Enters MDx Market With Lupus, Dermatology Gene Expression Assays
After nine years in business, precision medicine company AMPEL BioSolutions is broadening its market from pharmaceutical companies to healthcare providers and their patients.
AMPEL BioSolutions’ Machine Learning Breakthrough Predicts Drug Options for Inflammatory Skin Diseases
AMPEL BioSolutions announced a breakthrough in precision and personalized medicine that could revolutionize the way doctors treat inflammatory skin diseases, such as Lupus, Psoriasis, Atopic Dermatitis and Scleroderma.
New test may guide treatment of common skin diseases
Dermatologists routinely do skin biopsies to figure out what’s wrong with their patients. They study tissue under a microscope – looking at the structure of cells, but a Charlottesville company says doctors could treat disease more precisely by looking at genetics.
Nephrology
AMPEL BioSolutions Developing Molecular Test to Predict Kidney Damage in Lupus Nephritis Patients
According to the company, the test identifies molecular markers in kidney biopsy samples of LN patients, which can help reveal patients’ disease stage. This information, in turn, could help those pharmaceutical companies who have more than 45 LN drugs in development enroll patients in clinical trials with greater precision, AMPEL said.Â
AMPEL BioSolutions’ Breakthrough Predicts Drug Options to Slow End Stage Renal Disease
CLICK TO VIEW ORIGINAL ARTICLE > CHARLOTTESVILLE, Va., March 1, 2023 /PRNewswire/ — AMPEL BioSolutions today announced a genomic precision medicine test for chronic kidney diseases, such as Lupus Nephritis, that could save lives by predicting kidney damage before...
AMPEL BioSolutions’ Breakthrough Predicts Drug Options to Slow End Stage Renal Disease
CLICK TO READ ARTICLE > AMPEL BioSolutions announced a genomic precision medicine test for chronic kidney diseases, such as Lupus Nephritis, that could save lives by predicting kidney damage before it is irreversible and providing decision support for prophylactic...
Cardiology
New Blood Test to Help Physicians Prevent Major Cardiovascular Events in Women with Lupus
Now, a genetic precision medicine test for lupus patients could save lives by predicting heart disease before it happens and providing decision support for prophylactic therapies.
Lupus, coronary artery disease share genetic risk factors; data may lead to early testing
Researchers have identified shared genetic risk factors for systemic lupus erythematosus and coronary artery disease, according to data published in Cell Reports Medicine.
Heart Disease Blood Test
Ampel Bio-Solutions is working on a blood test that can find out if a person carries traits that may put them at higher risk of developing heart disease.
Fibromyalgia
This New Blood Test For Fibromyalgia Could Identify Your Best Treatment Options
Different from the FM/a blood test used for diagnosis, this new blood test for Fibromyalgia may be the key to your treatment plan.
Experimental Blood Test Could Improve Fibromyalgia Treatment
A small pilot study suggests an experimental blood test for fibromyalgia – called FibroGENE — could be used to determine which drug works best for each patient. Researchers at AMPEL BioSolutions and Duke University Medical Center found genetic biomarkers in the blood cells of 18 lupus patients with fibromyalgia-like symptoms.
AMPEL BioSolutions’ Breakthrough Predicts Drug Options for Fibromyalgia
AMPEL BioSolutions announced a breakthrough in precision and personalized medicine that could revolutionize the way doctors treat chronic pain syndromes, such as fibromyalgia. Revealed in the peer-reviewed journal Lupus Science and Medicine, the paper details AMPEL’s breakthrough approach to characterize the underlying disease activity from gene expression data obtained from patient blood samples.
COVID
Genomic tests help doctors treat COVID-19 and long COVID
With many COVID-19 treatments now available, a simple blood test can show doctors the best route to take. Charlottesville’s AMPEL BioSolutions says it can predict and detect the severity of a COVID-19 infection, as well as how to help a patient through its new genomic test called CovGENE.
AMPEL’s CovGENE blood test predicts COVID19 severity and holds promise for long COVID
AMPEL BioSolutions announced a breakthrough in precision and personalized medicine that can detect and predict the severity of COVID-19 in patients while also determining the best treatment options for each specific case.
New test shows whether someone infected with COVID will develop a bad case
While the COVID pandemic is easing in some places, the CDC says it’s the third leading cause of death for the third year in a row. Now, a Virginia company says it’s got a test that will help doctors determine which patients are at greatest risk so they can prescribe the best treatment.